Cardiovascular Drugs Practice Questions

Q: Which of the following drugs lack vasodilatory properties but are effective in angina?

Metoprolol. ***Metoprolol*** - **Metoprolol** is a beta-blocker that reduces myocardial oxygen demand by decreasing heart rate, contractility, and blood pressure, without direct vasodilatory effects. - Its efficacy in angina is primarily due to these **cardiac depressant actions**, which relieve myocardial ischemia. *Isosorbide dinitrate* - **Isosorbide dinitrate** is a nitrate that works by releasing nitric oxide, leading to **venodilation** and **arterial dilation**, particularly reducing preload and improving coronary blood flow. - Its anti-anginal effect is directly linked to its **vasodilatory properties**. *Nifedipine* - **Nifedipine** is a dihydropyridine calcium channel blocker that produces potent **vasodilation** of both coronary and peripheral arteries. - Its primary mechanism of action in angina involves **reducing afterload** and improving coronary blood flow through vasodilation. *Verapamil* - **Verapamil** is a non-dihydropyridine calcium channel blocker that causes **coronary and peripheral vasodilation**, reducing afterload and improving myocardial perfusion. - While it also reduces heart rate and contractility, its direct **vasodilatory effects** contribute significantly to its anti-anginal action.

Q: In a diabetic patient with hypertension, which of the following medications is the most suitable choice for management?

Enalapril. ***Enalapril*** - **ACE inhibitors** like enalapril are first-line agents in diabetic patients with hypertension due to their **renoprotective effects**, slowing the progression of **diabetic nephropathy**. - They reduce **glomerular pressure** and **albuminuria**, which is crucial in managing long-term complications of diabetes. *Propranolol* - **Beta-blockers** like propranolol can mask symptoms of **hypoglycemia** (e.g., tremors, palpitations), which is a significant concern in diabetic patients. - They may also worsen **insulin resistance** and negatively impact the lipid profile. *Clonidine* - **Clonidine**, an alpha-2 agonist, is typically reserved for **resistant hypertension** or specific conditions like **ADHD** due to its side effects. - It can cause significant **sedation**, **dry mouth**, and **rebound hypertension** upon sudden discontinuation, making it less suitable for routine management. *Hydrochlorothiazide* - **Thiazide diuretics** can cause adverse metabolic effects in diabetic patients, including **hyperglycemia** and worsening of **insulin resistance**. - While effective for hypertension, their metabolic profile makes them less preferred as a first-line agent in patients with diabetes.

Q: Which of the following enzymes is not targeted by hypolipidemic drugs?

Peripheral decarboxylase. ***Peripheral decarboxylase*** - **Peripheral decarboxylase** (also known as DOPA decarboxylase) is involved in the synthesis of dopamine from L-DOPA and is a target for drugs used in **Parkinson's disease**, not hypolipidemic drugs. - Its inhibition by drugs like **carbidopa** or **benserazide** prevents the peripheral conversion of L-DOPA to dopamine, increasing L-DOPA availability for the brain. *HMG Co A reductase* - **HMG-CoA reductase** is the rate-limiting enzyme in cholesterol biosynthesis and is the primary target for **statins** (e.g., atorvastatin, simvastatin). - Statins effectively lower **LDL cholesterol** by inhibiting this enzyme, reducing endogenous cholesterol production. *Lipoprotein lipase* - **Lipoprotein lipase (LPL)** activity can be enhanced by certain hypolipidemic drugs, such as **fibrates**, which activate **PPAR-α**. - Increased LPL activity leads to enhanced hydrolysis of **triglycerides** from VLDL and chylomicrons, reducing triglyceride levels in plasma. *Acyl CoA, cholesterol acyl transferase 1* - **Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors** were developed as potential hypolipidemic agents to prevent cholesterol esterification and absorption. - While not widely used clinically due to efficacy and side effect profiles, **ACAT1** is involved in cholesterol esterification in the intestine and liver, making it a target for reducing cholesterol absorption.

Q: All drugs decrease mortality in heart failure except:

Digoxin. ***Digoxin*** - **Digoxin** is known to improve symptoms and reduce hospitalizations in heart failure, but it has **not been shown to decrease mortality** in large clinical trials (DIG trial). - Its narrow **therapeutic window** and potential for toxicity, especially in patients with renal impairment, limit its use primarily to symptom management. *Metoprolol* - **Metoprolol succinate**, a beta-blocker, significantly reduces mortality and morbidity in patients with chronic heart failure with reduced ejection fraction (MERIT-HF trial) by blocking the deleterious effects of the sympathetic nervous system. - It works by reducing heart rate, myocardial oxygen demand, and cardiac remodeling. *Enalapril* - **Enalapril**, an ACE inhibitor, is a cornerstone medication in heart failure treatment due to its proven ability to reduce mortality, hospitalizations, and improve quality of life (CONSENSUS, SOLVD trials). - It works by blocking the **renin-angiotensin-aldosterone system**, leading to vasodilation, reduced preload and afterload, and prevention of cardiac remodeling. *Telmisartan* - **Telmisartan**, an ARB (angiotensin receptor blocker), is used as an alternative in heart failure patients who cannot tolerate ACE inhibitors due to side effects like cough. - ARBs as a class have shown mortality benefits in heart failure, acting by blocking the **angiotensin II type 1 receptor**, producing similar cardiovascular benefits to ACE inhibitors in terms of vasodilation and reduction in cardiac remodeling.

Q: Which calcium channel blocker is known to cause reflex tachycardia?

Nifedipine. ***Nifedipine*** - **Nifedipine** is a **dihydropyridine calcium channel blocker** that causes significant **peripheral vasodilation**. - This rapid drop in blood pressure activates the **baroreceptor reflex**, leading to an increase in heart rate (**reflex tachycardia**) to compensate. *Verapamil* - **Verapamil** is a **non-dihydropyridine calcium channel blocker** that acts on both vascular smooth muscle and cardiac conduction. - It has a direct negative chronotropic effect on the heart, which typically **prevents reflex tachycardia**. *Amlodipine* - **Amlodipine** is a **long-acting dihydropyridine calcium channel blocker** with a more gradual onset of action. - While it causes peripheral vasodilation, its **slow onset and prolonged duration** of action typically result in less pronounced or absent reflex tachycardia compared to nifedipine. *Diltiazem* - **Diltiazem** is a **non-dihydropyridine calcium channel blocker** with effects on both the heart and peripheral vasculature. - Similar to verapamil, its direct **negative chronotropic and dromotropic effects** on the heart prevent significant reflex tachycardia.

Q: How much decrease in LDL cholesterol and how much increase in HDL cholesterol can occur with the use of bile acid resins as anti-dyslipidemic drugs?

15-25% decrease in LDL-C and 3-5% increase in HDL-C. ***Correct: 15-25% decrease in LDL-C and 3-5% increase in HDL-C***- **Bile acid resins** (cholestyramine, colestipol, colesevelam) effectively lower **LDL cholesterol by 15-25%** by sequestering bile acids in the intestine, leading to increased hepatic LDL receptor expression [1].- They produce a modest but beneficial **3-5% increase in HDL cholesterol**.- This represents the typical therapeutic effect at standard doses.*Incorrect: 3-5% decrease in LDL-C and 1-3% increase in HDL-C*- This represents a **much smaller effect** on both LDL-C and HDL-C than typically observed with therapeutic doses of bile acid resins.- Such marginal LDL-C reduction (3-5%) would be **clinically insignificant** for most dyslipidemic patients requiring treatment.*Incorrect: 25-35% decrease in LDL-C and 1-3% increase in HDL-C*- While bile acid resins can achieve significant **LDL-C reduction**, the 25-35% range is on the **higher end** of what's typically seen (more common with maximum doses or combination therapy).- The **HDL-C increase of 1-3%** is lower than the standard 3-5% increase commonly reported for this drug class.*Incorrect: 5-10% decrease in LDL-C and 1-3% increase in HDL-C*- This magnitude of **LDL-C reduction is suboptimal** for patients requiring lipid-lowering therapy with bile acid resins.- Both the LDL-C decrease and HDL-C increase are below the expected therapeutic range for this medication class.

Q: All are fibric acid derivatives except which of the following?

Lovastatin. ***Lovastatin***- **Lovastatin** is an example of a **statin drug**, which works by inhibiting **HMG-CoA reductase**, the rate-limiting enzyme in cholesterol synthesis, primarily lowering LDL cholesterol [1, 2].- Unlike fibric acid derivatives, statins do not primarily target **PPAR-alpha** receptors to reduce triglyceride levels.*Clofibrate*- **Clofibrate** is an older **fibric acid derivative** that primarily activates **PPAR-alpha** receptors, leading to decreased triglyceride production and increased lipoprotein lipase activity [1, 2].- It is one of the earliest drugs in this class, though now largely replaced by newer agents due to side effects.*Gemfibrozil*- **Gemfibrozil** is a commonly used **fibric acid derivative** that activates **PPAR-alpha**, resulting in a reduction of **triglycerides** and an increase in **HDL cholesterol** [1, 2].- It is effective in treating severe hypertriglyceridemia and mixed dyslipidemia.*Fenofibrate*- **Fenofibrate** is a **fibric acid derivative** that, like gemfibrozil, acts as a **PPAR-alpha agonist** to lower triglycerides and raise HDL cholesterol [1, 2].- It also has a beneficial effect on **uric acid levels** and can be used in patients with hyperuricemia.

Q: What is the drug of choice in paroxysmal supraventricular tachycardia?

Adenosine. ***Adenosine*** - **Adenosine** is the drug of choice for acute termination of most paroxysmal supraventricular tachycardias (PSVT) due to its rapid onset and short duration of action [1]. - It works by transiently blocking the **atrioventricular (AV) node**, interrupting the re-entrant circuit common in PSVT [1]. *Amiodarone* - **Amiodarone** is a potent antiarrhythmic primarily used for both supraventricular and ventricular arrhythmias, but it is not the first-line agent for acute PSVT due to a slower onset of action and more significant side effects. - It is typically reserved for **refractory arrhythmias** or for maintaining sinus rhythm in patients with recurrent atrial fibrillation or flutter. *Lidocaine* - **Lidocaine** is primarily used for **ventricular arrhythmias**, particularly in the setting of acute myocardial infarction. - It has little to no efficacy in treating **supraventricular tachycardias** because its main action is on ventricular sodium channels. *Quinidine* - **Quinidine** is a Class IA antiarrhythmic drug used for various supraventricular and ventricular arrhythmias, but it is not the first-line treatment for acute PSVT. - Its use has declined due to a high incidence of side effects like **QT prolongation**, torsades de pointes, and gastrointestinal upset.

Q: Which anti-hypertensive drug is known to cause a positive Coombs' test, indicating potential autoimmune hemolytic anemia?

Methyldopa. ***Methyldopa*** - **Methyldopa** is a well-known antihypertensive drug that can induce a **positive Coombs' test** in a significant number of patients, indicating the presence of antibodies on red blood cells. - While many patients with a positive Coombs' test remain asymptomatic, a small percentage can develop **autoimmune hemolytic anemia**. *Clonidine* - **Clonidine** is an alpha-2 adrenergic agonist used to treat hypertension but is not typically associated with inducing a **positive Coombs' test** or hemolytic anemia. - Its primary side effects relate to its central nervous system action, such as **sedation** and **dry mouth**. *Hydralazine* - **Hydralazine** is a direct vasodilator that can cause a **drug-induced lupus-like syndrome**, but it is generally not associated with a **positive Coombs' test** or hemolytic anemia. - The lupus-like syndrome presents with symptoms like arthralgia, myalgia, and fever. *Sodium nitroprusside* - **Sodium nitroprusside** is a potent vasodilator used in hypertensive emergencies, working by releasing nitric oxide. - It is not associated with a **positive Coombs' test** or drug-induced hemolytic anemia; its primary toxicity concern is **cyanide poisoning** with prolonged or high-dose use.

Q: Which of the following is the MOST effective agent for prophylaxis of high-altitude pulmonary edema?

Acetazolamide. ***Acetazolamide*** - **Acetazolamide** is a **carbonic anhydrase inhibitor** and the **first-line prophylactic agent** for high-altitude pulmonary edema (HAPE). - It works by inducing **metabolic acidosis**, which stimulates **ventilation** and improves **oxygenation**, facilitating acclimatization to high altitude. - It reduces the incidence of **acute mountain sickness (AMS)** and has proven efficacy in **HAPE prevention** by improving arterial oxygenation and reducing pulmonary artery pressure. - Recommended dosing: **125-250 mg twice daily**, starting 1-2 days before ascent. *Nifedipine* - **Nifedipine** is a calcium channel blocker that causes pulmonary vasodilation and reduces pulmonary arterial pressure. - While effective for HAPE prevention, it is typically reserved as a **second-line agent** or for individuals with a **history of recurrent HAPE**. - It is more commonly used for **treatment** of established HAPE rather than primary prophylaxis. *ACE inhibitor* - **ACE inhibitors** primarily affect the systemic renin-angiotensin-aldosterone system and are used for **hypertension** and **heart failure**. - They do not have a direct role in reducing **pulmonary artery pressure** or preventing HAPE. - Not recommended for altitude illness prophylaxis. *Digoxin* - **Digoxin** is a cardiac glycoside used for **heart failure** and **atrial fibrillation** to increase cardiac contractility and control heart rate. - It has no role in preventing or treating **HAPE** as it does not reduce pulmonary vascular resistance or facilitate acclimatization. - Not used for altitude-related conditions.

Question 1

Which of the following drugs lack vasodilatory properties but are effective in angina?

Accepted Answer

Metoprolol

Answer

Isosorbide dinitrate

Answer

Nifedipine

Answer

Verapamil

Question 2

In a diabetic patient with hypertension, which of the following medications is the most suitable choice for management?

Accepted Answer

Enalapril

Answer

Clonidine

Answer

Hydrochlorothiazide

Answer

Propranolol

Question 3

Which of the following enzymes is not targeted by hypolipidemic drugs?

Accepted Answer

Peripheral decarboxylase

Answer

HMG Co A reductase

Answer

Lipoprotein lipase

Answer

Acyl CoA, cholesterol acyl transferase 1

Question 4

All drugs decrease mortality in heart failure except:

Accepted Answer

Digoxin

Answer

Enalapril

Answer

Metoprolol

Answer

Telmisartan

Question 5

Which calcium channel blocker is known to cause reflex tachycardia?

Accepted Answer

Nifedipine

Answer

Verapamil

Answer

Amlodipine

Answer

Diltiazem

Question 6

How much decrease in LDL cholesterol and how much increase in HDL cholesterol can occur with the use of bile acid resins as anti-dyslipidemic drugs?

Accepted Answer

15-25% decrease in LDL-C and 3-5% increase in HDL-C

Answer

3-5% decrease in LDL-C and 1-3% increase in HDL-C

Answer

25-35% decrease in LDL-C and 1-3% increase in HDL-C

Answer

5-10% decrease in LDL-C and 1-3% increase in HDL-C

Question 7

All are fibric acid derivatives except which of the following?

Accepted Answer

Lovastatin

Answer

Clofibrate

Answer

Gemfibrozil

Answer

Fenofibrate

Question 8

What is the drug of choice in paroxysmal supraventricular tachycardia?

Accepted Answer

Adenosine

Answer

Amiodarone

Answer

Quinidine

Answer

Lidocaine

Question 9

Which anti-hypertensive drug is known to cause a positive Coombs' test, indicating potential autoimmune hemolytic anemia?

Accepted Answer

Methyldopa

Answer

Clonidine

Answer

Hydralazine

Answer

Sodium nitroprusside

Question 10

Which of the following is the MOST effective agent for prophylaxis of high-altitude pulmonary edema?

Accepted Answer

Acetazolamide

Answer

ACE inhibitor

Answer

Nifedipine

Answer

Digoxin

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?